What are the characteristics of IPSEN stock?

IPSEN is a company operating in the Santé · Vaccins et laboratoires de recherche sector. The stock is listed on Euronext Paris under ISIN FR0010259150.

What is the recent price evolution of IPSEN stock?

Since last close: -0.19 %. Over one week: 3.48 %. Over one year: 51.54 %.

Ipsen: Transfer of Shares from Beech Tree to Alasol Foundation

Ipsen has announced the transfer of shares from Beech Tree company to the Alasol Foundation, in accordance with the wishes of Mr. Henri Beaufour.

Published on Dec 05, 2025 at

IPSEN

157.60 € -0.19 %

Details of the Transfer

According to the press release, the shares of Beech Tree, the holding company owning Mr. Henri Beaufour's stake in Ipsen, will be transferred to the Alasol Foundation at the beginning of 2026. This transfer is subject to the necessary regulatory approvals.

Impact on Shareholder Agreement

Free · Every morning

Technical market signals, before the opening bell.

Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.

✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis

Indicative data. No investment advice. Unsubscribe at any time.

The company indicates that this transfer of shares will not affect the existing shareholder agreement between Beech Tree and Highrock.

Mission of the Alasol Foundation

The Alasol Foundation, established by Mr. Beaufour, is dedicated to promoting education and professional training for disadvantaged children and young adults.

🏢 Other stocks — Santé

🗞️ ABL Diagnostics Submits Takeover Bid for Texcell Amid Bankruptcy Proceedings 🗞️ Sensorion Prioritizes SENS-601 as Main Program and Discontinues SENS-501 🗞️ Sanofi Halts Phase 3 MOBILIZE Study on Riliprubart Following Unfavorable Interim Analysis 🗞️ IBA Partners with MD Anderson to Assess Clinical and Economic Value of Proton Therapy

Context

Period

Period: 1T2026

Key reported figures

Revenue: 1074.9M€

Guidance from the release

Ipsen a réalisé un excellent début d'année 2026.
Croissance soutenue grâce aux trois aires thérapeutiques.

Risks mentioned

pression réglementaire anticipée sur de nouveaux médicaments
concurrence accrue sur Somatuline à cause des génériques

Opportunities identified

croissance des ventes totales du Groupe supérieure à 13,0 %
lancement de trois nouveaux programmes en phase avancée

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Details of the Transfer

Impact on Shareholder Agreement

Mission of the Alasol Foundation

Context

Also read